Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product ...

根据最新的SEC文件显示，Neurocrine Biosciences Inc. (NASDAQ: NBIX )的首席医疗官Eiry ...

根据提交给美国证券交易委员会的文件显示，Neurocrine Biosciences Inc. (NASDAQ: NBIX )的首席法务官Darin ...

Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $185 from $170 and keeps an Overweight rating on the shares. The share ...

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) on January 31 and set a price target of ...